Review Article| Volume 102, ISSUE 3, P493-498, June 2022

Chemo and Immuno-Therapeutic Options for Nonsmall Cell Lung Cancer Lung Cancer


      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribers receive full online access to your subscription and archive of back issues up to and including 2002.

      Content published before 2002 is available via pay-per-view purchase only.


      Subscribe to Surgical Clinics
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Herbst R.S.
        • Baas P.
        • Kim D.W.
        • et al.
        Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial.
        Lancet. 2016; 387: 1540-1550
        • Borghaei H.
        • Paz-Ares L.
        • Horn L.
        • et al.
        Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer.
        N Engl J Med. 2015; 373: 1627-1639
        • Reck M.
        • Rodríguez-Abreu D.
        • Robinson A.G.
        • et al.
        Updated analysis of KEYNOTE-024: pembrolizumab versus platinum-based chemotherapy for advanced non-small-cell lung cancer with PD-L1 tumor proportion score of 50% or greater.
        J Clin Oncol. 2019; 37: 537-546
        • Mok T.S.K.
        • Wu Y.L.
        • Kudaba I.
        • et al.
        Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial.
        Lancet. 2019; 393: 1819-1830
        • Herbst R.S.
        • Giaccone G.
        • de Marinis F.
        • et al.
        Atezolizumab for first-line treatment of PD-L1-selected patients with NSCLC.
        N Engl J Med. 2020; 383: 1328-1339
        • Gadgeel S.
        • Rodríguez-Abreu D.
        • Speranza G.
        • et al.
        Updated analysis from KEYNOTE-189: pembrolizumab or placebo plus pemetrexed and platinum for previously untreated metastatic nonsquamous non-small-cell lung cancer.
        J Clin Oncol. 2020; 38: 1505-1517
        • West H.
        • McCleod M.
        • Hussein M.
        • et al.
        Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial.
        Lancet Oncol. 2019; 20: 924-937
        • Hellmann M.D.
        • Paz-Ares L.
        • Bernabe Caro R.
        • et al.
        Nivolumab plus ipilimumab in advanced non-small-cell lung cancer.
        N Engl J Med. 2019; 381: 2020-2031
        • Friedlaender A.
        • Liu S.V.
        • Addeo A.
        Tracking the tail.
        J Immunother Cancer. 2020; 8: e000971
        • Boyer M.
        • Şendur M.A.N.
        • Rodríguez-Abreu D.
        • et al.
        Pembrolizumab plus ipilimumab or placebo for metastatic non-small-cell lung cancer with PD-L1 tumor proportion score ≥ 50%: Randomized, double-blind phase III KEYNOTE-598 study.
        J Clin Oncol. 2021; 39: 2327-2338
        • Faivre-Finn C.
        • Vicente D.
        • Kurata T.
        • et al.
        Four-year survival with durvalumab after chemoradiotherapy in stage III NSCLC-an update from the PACIFIC trial.
        J Thorac Oncol. 2021; 16: 860-867
        • Antonia S.J.
        • Villegas A.
        • Daniel D.
        • et al.
        Overall survival with durvalumab after chemoradiotherapy in stage III NSCLC.
        N Engl J Med. 2018; 379: 2342-2350
        • Hui R.
        • Özgüroğlu M.
        • Villegas A.
        • et al.
        Patient-reported outcomes with durvalumab after chemoradiotherapy in stage III, unresectable non-small-cell lung cancer (PACIFIC): a randomised, controlled, phase 3 study.
        Lancet Oncol. 2019; 20: 1670-1680
        • Felip E.
        • Rosell R.
        • Maestre J.A.
        • et al.
        Preoperative chemotherapy plus surgery versus surgery plus adjuvant chemotherapy versus surgery alone in early-stage non-small-cell lung cancer.
        J Clin Oncol. 2010; 28: 3138-3145
        • NSCLC M-aCG.
        Preoperative chemotherapy for non-small-cell lung cancer: a systematic review and meta-analysis of individual participant data.
        Lancet. 2014; 383: 1561-1571
        • Friedlaender A.
        • Naidoo J.
        • Banna G.L.
        • et al.
        Role and impact of immune checkpoint inhibitors in neoadjuvant treatment for NSCLC.
        Cancer Treat Rev. 2022; 104: 102350
        • Kwiatkowski D.J.
        • Rusch V.W.
        • Chaft J.E.
        • et al.
        Neoadjuvant atezolizumab in resectable non-small cell lung cancer (NSCLC): interim analysis and biomarker data from a multicenter study (LCMC3).
        J Clin Oncol. 2019; 37: 8503
        • Spicer J.
        • Wang C.
        • Tanaka F.
        • et al.
        Surgical outcomes from the phase 3 CheckMate 816 trial: Nivolumab (NIVO) + platinum-doublet chemotherapy (chemo) vs chemo alone as neoadjuvant treatment for patients with resectable non-small cell lung cancer (NSCLC).
        J Clin Oncol. 2021; 39: 8503
        • Mouillet G.
        • Monnet E.
        • Milleron B.
        • et al.
        Pathologic complete response to preoperative chemotherapy predicts cure in early-stage non-small-cell lung cancer: combined analysis of two IFCT randomized trials.
        J Thorac Oncol. 2012; 7: 841-849
        • Waser N.A.
        • Adam A.
        • Schweikert B.
        • et al.
        Pathologic response as early endpoint for survival following neoadjuvant therapy (NEO-AT) in resectable non-small cell lung cancer (rNSCLC): systematic literature review and meta-analysis.
        Ann Oncol. 2020; 31: S806